

FACTSHEET



ENHANCING GLOBAL HEALTHCARE

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, oncology and immunology. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development.

Biocon Biologics, a subsidiary of Biocon Ltd, is uniquely positioned as a fully integrated 'pure play' biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions. It has a platform of 28 biosimilar molecules across diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases. The Company has five of its biosimilars commercialized in the developed markets like U.S., EU, Canada, Japan and Australia. It aspires to benefit 5 million patient lives with its biosimilars and attain a revenue milestone of USD 1 billion in FY22.

Syngene, our publicly listed subsidiary, is an innovation-focused global discovery, development and manufacturing organisation providing integrated scientific services to life sciences companies around the world.

VISION

To enhance global healthcare through innovative and affordable biopharma products for patients, partners and healthcare systems across the globe.

MISSION

To be an integrated biotechnology enterprise of global distinction.

GLOBAL PRESENCE



Patents granted



800+ Registered trademarks

A CREDIBLE BIOPHARMA ENTERPRISE



Biologics taken from Lab to Market; 2 Novels & 5 Biosimilars



25+ cGMP approvals from International regulatory agencies*



Ranked 6 Among Top 10 Global Biotech Employers by Science magazine

Key Brands INSUGEN[®] (rh-insulin), Basalog One[®] (prefilled Glargine pen), CANMAb[™] (Trastuzumab), KRABEVA[®] (Bevacizumab), BIOMAb-EGFR[®] (Nimotuzumab) and ALZUMAb[™] (Itolizumab)

GROWTH VERTICALS: ALIGNED WITH SHIFTING PARADIGMS

From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality and affordable healthcare products & services globally.



Ensuring access through quality, affordability, reliability






Partnering to deliver innovative scientific solutions



Pushing scientific boundaries to deliver impactful innovations



Expanding access through innovative, inclusive healthcare solutions



Offering patients high quality, differentiated therapies

BIOCON AT A GLANCE

Biocon is leveraging its affordable innovation model to reduce disparities in access to safe, high-quality medicines, as well as, address the gaps in scientific research to find innovative solutions to impact a billion lives.

ATT I











₹**7,482**

Million profit for

27%


EBITDA margin*

the year*



*All the numbers are FY20

OUR REVENUES



GLOBAL SCALE MANUFACTURING CAPABILITIES IN INDIA

- Largest Biologics Manufacturing capability in India State-of-the-art manufacturing facilities mammalian & microbial
- Facilities conform to most stringent cGMP guidelines New sterile injectables facility commercialized in FY20
- New state-of-the-art monoclonal antibodies facility commissioned in FY20
- Regulatory approvals-EMA, US FDA, Health Canada, ANVISA, COFEPRIS, PMDA, TGA, MCC etc.



MANUFACTURING LOCATIONS Bangalore | Telangana | Visakhapatnam | Malaysia

Biocon Limited, 20th KM, Hosur Road, Electronic City, Bangalore, India 560 100 Phone: +91 80 2808 2808/91 80 4014 4014 | Fax: +91 80 2852 3423 Email: contact.us@biocon.com | Website: www.biocon.com Twitter: @Bioconlimited | LinkedIn: /company/biocon/ | Facebook: @Bioconlimited

Follow us at 😤 🌐 🎔 🕤 in